In the Phase II MAIA lung cancer trial, THIO improved patients’ overall survival when taken in combination with Libtayo.

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

Detailed results will be presented at an upcoming medical meeting and will be shared with regulatory ... research across diverse stages of skin cancer.” The potential use of Libtayo described above is ...

Information regarding our use of non-GAAP financial ... and present these results at a medical meeting later this year. This dataset reinforces our belief that Libtayo provides a best-in-class ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

These findings are expected to be presented at a medical ... Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new application as an ...

The National Institutes of Health (NIH) defines precision oncology as a form of treatment where medical professionals ... the company’s cancer medicine Libtayo brought in $289 million in sales ...